Vamil Divan, Guggenheim Securities analyst, joins ‘Squawk on the Street’ to discuss Pfizer’s guidance, how optimistic Divan is on Pfizer’s product pipeline, and some of the complaints Pfizer has heard from activist investor Starboard.
Vamil Divan, Guggenheim Securities analyst, joins ‘Squawk on the Street’ to discuss Pfizer’s guidance, how optimistic Divan is on Pfizer’s product pipeline, and some of the complaints Pfizer has heard from activist investor Starboard.